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Abstract
Background: Mainstreaming genetic medicine, increased media coverage and clinical trials for BRCA mutation
carriers are leading oncologists into more patient discussions about BRCA genetic testing. BRCA variants of uncertain
significance (VUS) occur in 10–20 % of tests. VUS detection introduces additional uncertainty for patient and
potentially clinician. We aimed to explore the ability of breast cancer specialists (BCS) in the UK to correctly
respond to a VUS report.
Methods: A survey sent to 800 UK BCS collected demographics data, VUS general knowledge and interpretation and
communication based on two genetics reports. A separate survey of UK clinical geneticists collected demographics
data, laboratory reporting practice and methods used to clarify VUS pathogenicity including classification systems.
Results: Of the 155 BCS (22.5 %) who completed the survey, 12 % reported no genetics training. Ninety five percent
referred patients for BRCA genetic tests, 71 % felt unsure about the clinical implications of the test reports presented
here. A VUS report from a patient with a positive family history was interpreted and theoretically communicated
correctly by 94 % but when presented with a different VUS report with no management guidance and negative
family history, 39 % did not know how to communicate this result to the patient. Geneticists reported multiple
VUS classification systems; the most commonly used was word-based in 32 %.
Conclusions: A consistent and standardised format to report particularly VUS results across all diagnostic
laboratories plus additional training of UK BCS will be necessary for effective mainstreaming of BRCA testing to
the oncology clinic.
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Background
Pathogenic mutations in the BRCA1 and BRCA2 genes
confer a high lifetime risk of breast (and ovarian) can-
cers [1]. Over the 19 years since the identification of the
BRCA1 and BRCA2 genes [2, 3]; genetic testing requests
to identify pathogenic mutations in BRCA1 and BRCA2
have risen steadily. NHS BRCA testing in the UK was
introduced gradually from the mid 1990’s and has trad-
itionally been delivered through a clinical genetics model
driven typically by a strong family history of breast
cancer. Demand on the genetics service has increased
steadily, with peaks of referral for testing sparked by
greater public awareness from press reporting of high
profile figures such as Angelina Jolie [4, 5]. A growing
interest by oncologists in novel targeted approaches to
the management of triple negative breast tumours,
together with recognition that this phenotype, (particu-
larly at young ages), is associated with a higher fre-
quency of BRCA1 mutation carriers, has also increased
requests for more rapid access to genetic testing [4].
Young onset triple negative breast cancer cases are
eligible for genetic testing even without a family history
of breast or ovarian cancer [6]. Faster access to genetic
testing without the need for referral to genetics specialists
is one of the aims of the “Mainstreaming of genetic
testing” agenda [7].
A BRCA genetic test can yield 3 possible results:
Positive (a pathogenic mutation is found), negative
(no mutation detected or a variant of no clinical
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significance – a polymorphism) or a variant of uncer-
tain significance (VUS). A VUS is an alteration in the
gene sequence with unknown consequences on the
function of the gene product or risk of causing dis-
ease. One classification proposed in 2008 by a work-
shop of experts convened at the International Agency
for Research into Cancer, suggested a 5 point classifi-
cation scheme following a parallel system to that used
in reporting cytology or radiology results [8]. The
scheme classifies mutations that are irrefutably patho-
genic as class 5, and class 4 variants have a probabil-
ity of being pathogenic of greater than 95 % taking
into account all available data about the variant which
may be derived from many different sources. Class 4
and 5 variants can be used for predictive testing in
unaffected relatives. A class 3 variant (VUS) has a
0.05–0.949 probability of being pathogenic; evidence
may be limited or conflicting and the closer to 95 %
probability a variant reaches, the more useful add-
itional family and functional studies are to improve
the classification. Therefore Class 3 variants are usu-
ally reported out by diagnostic laboratories in order
to facilitate further studies. Some of these variants be-
have as low penetrance gene mutations and should
not be managed in the same way as a highly pene-
trant mutation [9]. This is a complex concept to
communicate to a patient who may have undertaken
genetic testing with the main aim of gaining access to
new treatment options. A class 3 variant would not
allow them to be entered into trials aimed at carriers
of clearly pathogenic mutations. Most will not have
any functional effect but some may have relevance for
other family members.
The frequency of VUS reports from different labora-
tories varies worldwide and depends on testing preva-
lence and the ancestry of the population served. In
African-American populations the rate can be up to
21 %, 5–6 % in individuals of European ancestry in the
USA, and 15 % in European laboratories [10, 11]. A rec-
ord of over 1500 VUS results [12] (as well as pathogenic
BRCA1 and BRCA2 coding variants) is held in a number
of publicly accessible databases. However, these data-
bases vary in how well annotated and curated they are
and no public databases currently permit an iterative
process of gathering cumulative evidence to reclassify
variants. NHS (National Health Service) genetic testing
laboratories undergo a national quality assurance
scheme to review detection rates of pathogenic muta-
tions and ensure that the Association for Clinical
Genetics Science (ACGS) guidelines for assessing the
pathogenicity of variants are observed, although these
are not specific for the BRCA genes [13]. However there
is no standard template for BRCA reporting and no
nationally adopted classification scheme.
Testing recently diagnosed breast cancer patients as
opposed to testing unaffected individuals brings unique
challenges with complex issues that require careful con-
sideration and a multidisciplinary approach. Common
queries include the optimum timing of the genetic test
in relation to the patient’s cancer treatment, selecting
which patients without a family history require a genetic
test and deciding the management of a patient with a
very strong family history but a negative BRCA genetic
test result as well as what to do with a VUS result. In
the UK, a 2011 report from the Foundation for Genom-
ics and Population Health (PHG foundation), “Genetics
and mainstream medicine” set out a new strategy
whereby in the future medical specialities including on-
cologists will incorporate genetics into their standard
practise supported by higher level regional genetics ser-
vices [7]. The Royal Marsden Hospital is currently pilot-
ing the move of BRCA genetic testing in breast and
ovarian cancer patients away from the genetic clinics
into a combined oncology-genetics model. The advan-
tages of more patients having access to genetic tests and
a more streamlined process must be balanced with con-
cerns about whether oncologists are prepared or
equipped to take on not only the ‘easy’ results but issues
such as what to tell the patient when the significance of
the result is uncertain.
Previous work has looked at patients’ [14], General
Practitioners’ [15, 16] and medical specialists’ know-
ledge of BRCA genetic testing, [17, 18] including on-
cologists’, [19] but there is little published describing
the knowledge of non-geneticist breast cancer special-
ists particularly with regard to a VUS result. The only
study to our knowledge specifically looking at BRCA
VUS knowledge is a survey of genetic counsellors in
the US [20] where significant variation in personal in-
terpretation and management recommendations
existed. Another study of patients with a VUS, refer-
ring family physicians and genetic counsellors con-
cluded that national VUS-related guidelines were
required [21].
In this study we aimed to explore the current know-
ledge among breast oncologists and breast surgeons at
specialist training/registrar and consultant level UK-wide
of how to use a VUS result. We explored whether clini-
cians made correct interpretations and appropriate man-
agement choices when presented with two anonymised
patient genetics test results taken verbatim from 2 differ-
ent UK genetics laboratories reporting a VUS result. To
place this in context we also approached medical geneti-
cists to gain an insight into the variations in laboratory
practice in interpreting and reporting VUS results. This
variation in reporting styles from individual laborator-
ies may not be known to individual BCS, but as
trainees and consultants work in different UK
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geographical regions during their career the issue of
heterogeneity within UK genetics laboratories is an
important point to illustrate.
Methods
Ethical approval was not required for this survey. Per-
sonal, sensitive personal and confidential data was not
collected from study participants. Written consent was
not required for these quantitative survey, however im-
plied consent was taken by participating in the anonym-
ous survey. Participants were informed that answers
were going to be used for publication. The collection
method by “survey monkey” and questions meant no
identifiable data was collected and the response could
not be linked by the researchers to an individual.
Breast cancer specialists survey - questionnaire 1
A questionnaire was sent electronically in September 2013
to all members of 3 large national organisations: the UK
Breast Intergroup, the Association of Cancer Physicians
and the Association of Breast Surgeons. Members of these
mailing lists included medical and clinical oncologists spe-
cialising in breast cancer and breast surgeons, at specialist
trainee or consultant level practising within the UK. The
breast specialists’ questionnaire was designed by the au-
thors with 10 questions and included questions on demo-
graphics, level of genetics training, referral practice for
genetic testing, general knowledge of VUS and the inter-
pretation and communication of two anonymised genetic
test results reporting a VUS which had been issued by two
different UK NHS diagnostic laboratories transcribed ver-
batim. Additional file 1: Report 1 summary: “A missense
mutation in exon 11 BRCA2 gene (unclassified variant)
and change in exon 13 of BRCA2 (rare polymorphism)”.
Additional file 1: Report 2 summary: “Heterozygous for
BRCA2 c.9098C > T, p.Thr3033lle (clinical significance
unknown)”. Full reports and questions are provided in
Additional file 1. The questions were close-ended with
limitations on multiple responses except for the commu-
nication to patients of the two genetics reports. Free text
boxes were included to capture further responses and to
allow for qualitative analysis.
The term VUS was deliberately not included in the
questions about communication of the report to pa-
tients, so respondents could not just intelligently guess
the answer in the knowledge this was a survey about
VUS. The six responses (and other-free text box) were
further categorised into appropriate, inappropriate and
don’t know responses to allow significance testing be-
tween specialities. Appropriate responses, as determined
by experts in cancer genetics, were “Explain there may
be a hereditary cause and discuss further tests” and
“Refer patients to a genetics consultant”. Inappropriate
responses were “Reassure the patient that there is no
hereditary cause for her breast cancer”, “Explain BRCA2
mutation contributed to causing her breast cancer”, and
“Explain she has a BRCA2 mutation discuss risk redu-
cing options”. Don’t know also included blank responses.
Responses from the free text were reviewed and classi-
fied into the appropriate category by BKE.
Geneticists survey - questionnaire 2
The second survey was also sent electronically from the
ENIGMA group (Evidence-based network for the interpret-
ation of germline mutant alleles) to Medical Geneticists in
December 2012 and January 2013; only respondents work-
ing in the UK have been included.
The geneticists’ questionnaire included study partici-
pants demographics questions and level of clinical ex-
perience, referral patterns, laboratory workload, BRCA
and VUS reporting proportions, actions to clarify clinical
significance of VUS and classification systems used.
Statistical analysis
Analysis was performed in STATA ver. 11.2. Descriptive
statistics were used to describe the study population char-
acteristics. Differences between disciplines (oncologist ver-
sus surgeon) in Table 2 were tested by Pearson chi
squared test. Communication of the report to patients
were categorised in dichotomous variables appropri-
ate/inappropriate and ‘don’t know.’ Fishers exact test
was used to test differences in communication of
report to patients by speciality excluding don't know
responses. Free text comments were scored manually
and results recorded thematically.
Results
Breast cancer specialists survey – questionnaire 1
The breast cancer specialist’s questionnaire was sent to
800 medical and clinical oncologists and breast surgeons
of registrar or consultant grade in September 2013 with
181 (22.5 %) responses. Medical oncologists within the
UK are specifically trained in the management in cancer
using systemic anticancer therapies only. Clinical (radi-
ation) oncologists within the UK are trained in both
radiotherapy techniques and systemic anticancer therap-
ies. Responses from allied professionals (nurses/geneti-
cists/radiologists/pathologists/trials staff ) were excluded
leaving 155 eligible respondents. The most frequent age
category was 40–50 years old (34.8 %). Three quarters of
respondents were consultants, and three quarters
oncologists.
Most specialists (74.2 %) had genetics training in med-
ical school or as part of their postgraduate exams, with
11.6 % stating they had received no genetics training
(Table 1). However the majority (95.3 %) had directly re-
ferred patients to a genetics service for genetic testing.
There was no significant difference between the
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specialities in terms of genetics training or referral to
genetics departments. Overall 71.0 % of respondents felt
unsure, uncomfortable or ill-equipped to interpret a gen-
etics report. The distribution of responses was signifi-
cantly different between surgeons and medical
oncologists (p = 0.030), but non-significant between
surgeons and clinical oncologists (p = 0.066) and clin-
ical and medical oncologists (p = 0.831). The surgeons
were also more confident (50.0 %) than oncologists
(24.1 % clinical oncologists and 38.1 % medical oncol-
ogists) in perceived understanding of a VUS (surgeons
vs medical oncologists p = 0.073, surgeons vs clinical
oncologist p = 0.003) but with no difference in the
distribution of responses between oncology specialities
(p = 0.234). When asked how frequently a VUS is re-
ported all three specialities gave 10–20 % as the most
common response.
Genetics report 1 (a female breast cancer patient with
a strong family history) provided the reader with the fol-
lowing summary “missense mutation in exon 11 of the
BRCA2 gene”. In the more detailed interpretation it
states that it “has previously been reported as an unclas-
sified variant”, that “this sequence change reduces
RAD51C binding activity” and “it may not be appropri-
ate to offer pre-symptomatic testing until pathogenicity
has been confirmed” and screening of at risk relatives
Table 1 Genetics training, referrals and VUS knowledge by breast cancer specialists
Total Medical oncologist Clinical oncologist Surgeon
No. (%) No. (%) No. (%) No. (%)
155 (100 %) 63 (40.7 %) 54 (34.8 %) 38 (24.5 %)
Genetics training
None 18 (11.6 %) 9 (14.3 %) 5 (9.3 %) 4 (10.5 %)
Medical school/postgrad exams 115 (74.2 %) 47 (74.6 %) 44 (81.5 %) 24 (63.2 %)
Genetics course 4 (3.6 %) 2 (3.2 %) 1 (1.9 %) 1 (2.6 %)
Module with genetics service 1 (0.7 %) 0 (0 %) 1 (1.9 %) 0 (0 %)
Specialist interest (no formal training) 9 (5.8 %) 2 (3.2 %) 1 (1.9 %) 6 (15.8 %)
Higher degree 5 (3.2 %) 2 (3.2 %) 2 (3.7 %) 1 (2.6 %)
Othera 3 (1.9 %) 1 (1.6 %) 0 (0 %) 2 (5.3 %)
Direct genetics service referral
Yes 143 (95.3 %) 59 (93.7 %) 49 (96.1 %) 35 (97.2 %)
No 7 (4.7 %) 4 (6.4 %) 2 (3.9 %) 1 (2.8 %)
Missing 5 (3.2 %) 0 (0 %) 3 (5.3 %) 2 (5.6 %)
Ability to interpret genetics report
Yes 45 (29.0 %) 14 (22.2 %) 13 (24.1 %) 18 (47.4 %)
No 64 (41.3 %) 27 (42.9 %) 25 (46.3 %) 12 (31.6 %)
Unsureb 46 (29.7 %) 22 (34.9 %) 16 (29.6 %) 8 (21.1 %)
VUS understanding
Fully understand 56 (36.1 %) 24 (38.1 %) 13 (24.1 %) 19 (50.0 %)
Don't fully understand 66 (42.6 %) 25 (39.7 %) 24 (44.4 %) 17 (44.7 %)
Not heard/don't understand 33 (21.3 %) 14 (22.2 %) 17 (31.5 %) 2 (5.3 %)
How common is a VUS?
<10 % 26 (21.1 %) 9 (17.0 %) 13 (31.0 %) 5 (15.2 %)
10–20 % 61 (47.7 %) 29 (54.7 %) 15 (35.7 %) 17 (51.5 %)
20–30 % 24 (18.8 %) 11 (20.8 %) 8 (19.1 %) 5 (15.2 %)
30–40 % 11 (8.6 %) 4 (7.6 %) 3 (7.1 %) 4 (12.1 %)
40–50 % 2 (1.6 %) 0 (0 %) 2 (4.8 %) 0 (0 %)
>50 % 3 (2.3 %) 0 (0 %) 1 (2.4 %) 2 (6.1 %)
Don't’ know/skipped Q 27 (17.4 %) 10 (15.9 %) 12 (22.2 %) 5 (13.2 %)
a“Close cooperation with genetics over last 15 years – personal reading”, “Msc Module” “Experience in Genomics lab”
bIf 2 answers were given (eg No/Unsure) this was interpreted as ‘Unsure’
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may help to clarify whether this is a disease-causing mu-
tation in this family”. Only one interpretation of this re-
port was allowed in the questionnaire and the response
option most consistent with a VUS was “a gene muta-
tion found but unknown if causing her breast cancer.”
A clear majority (83.9 %) chose this response, only
13.6 % responded they “didn’t know” and there were
no responses that either a pathogenic BRCA2 muta-
tion was found or that no pathogenic mutation was
found (Table 2).
When asked how report 1 would be communicated
by the specialist to the patient and future manage-
ment options any number of responses were allowed
(Table 2). Most specialists (61.2 %) would have ex-
plained to the patient there may be a hereditary
cause and discuss further tests, as consistent with
the lab report interpretation provided. Most would
refer the patient to a genetics consultant (52.2 %)
and only 4.5 % said they “didn’t know”. After cate-
gorising the responses of communication to patients
for report 1 (Table 3), 94.2 % of specialists gave
appropriate responses with statistical significance be-
tween speciality responses (surgeon versus medical
oncologists p = 0.024, surgeon versus clinical oncolo-
gists p = 0.675, clinical oncologists versus medical
oncologists p = 0.171).
Genetics report 2 (from a female breast cancer patient
with negative family history) was summarised as: “Het-
erozygous for BRCA2 c.9098C > T”. Further information
in the report included statements “not previously re-
ported” and “significance unknown”, with no guidance
on management. The BCS interpretation of this report
Table 2 Interpretation of two genetics reports by breast cancer specialists
Total Medical oncologist Clinical oncologist Surgeon
No. (%) No. (%) No. (%) No. (%)
155 (100 %) 63 (40.7 %) 54 (34.8 %) 38 (24.5 %)
Interpretation of report 1
No pathogenic mutation 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
A gene mutation found but unknown if causing her breast cancer 130 (83.9 %) 57 (90.5 %) 45 (83.3 %) 28 (73.7 %)
A pathogenic BRCA2 gene mutation 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Don’t know 21 (13.6 %) 5 (7.9 %) 8 (14.8 %) 8 (21.1 %)
Other 4 (2.6 %) 1 (1.6 %) 1 (1.9 %) 2 (5.3 %)
Communication to patient report 1a
Reassure the patient that there is no hereditary cause for her breast cancer. 1 (0.6 %) 0 (0 %) 1 (1.9 %) 0 (0 %)
Explain there may be a hereditary cause and discuss further tests. 95 (61.2 %) 45 (71.4 %) 29 (53.7 %) 21 (55.3 %)
Explain BRCA2 mutation contributed to causing her breast cancer. 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Explain she has a BRCA2 mutation discuss risk reducing options. 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Refer patients to a genetics consultant. 81 (52.2 %) 36 (57.1 %) 30 (55.6 %) 15 (39.5 %)
Don't know. 7 (4.5 %) 0 (0 %) 3 (5.6 %) 4 (10.5 %)
Other (free text) 11 (7.1 %) 4 (6.3 %) 2 (3.7 %) 5 (13.2 %)
Interpretation of report 2
No pathogenic mutation 35 (22.6 %) 18 (28.6 %) 10 (18.5 %) 7 (18.4 %)
A gene mutation found but unknown if causing her breast cancer 71 (45.8 %) 31 (49.2 %) 23 (42.6 %) 17 (44.7 %)
A pathogenic BRCA2 gene mutation 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Don't Know 49 (31.6 %) 14 (22.2 %) 21 (38.9 %) 14 (36.8 %)
Communication to patient report 2a
Reassure the patient that there is no hereditary cause for her breast cancer. 10 (6.5 %) 2 (3.2 %) 2 (3.7 %) 6 (15.8 %)
Explain there may be a hereditary cause and discuss further tests. 13 (8.4 %) 7 (11.1 %) 3 (5.6 %) 3 (7.9 %)
Explain BRCA2 mutation contributed to causing her breast cancer. 1 (0.6 %) 0 (0 %) 1 (1.9 %) 0 (0 %)
Explain she has a BRCA2 mutation discuss risk reducing options. 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Refer patients to a genetics consultant. 68 (43.8 %) 24 (38.1 %) 24 (44.4 %) 14 (36.8 %)
Don't know/no answer 58 (37.4 %) 25 (39.7 %) 22 (40.7 %) 11 (28.9 %)
Other (free text) 12 (7.7 %) 5 (7.9 %) 2 (3.7 %) 5 (13.2 %)
aNumbers do not add to 100 % as multiple responses allowed
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was more mixed with 45.8 % stating “a gene mutation
found but unknown if causing her breast cancer”, 22.6 %
stating no pathogenic mutation found and 31.6 % don’t
know (Table 2).
In terms of communication and possible future man-
agement of the patient, 43.8 % of BCS would refer her to
a genetics consultant and 37.4 % responded “don’t know
or no response given.” 6.5 % would reassure the patient
there was no hereditary cause for her breast cancer and
8.4 % would say there was a hereditary cause and discuss
further tests (Table 2).
Again after all the communication responses were cate-
gorised, only 53.5 % were appropriate responses and
39.4 % don't know (Table 3). No significant differences be-
tween response by specialty were found (surgeon versus
medical oncologists, p = 0.084, surgeon versus clinical on-
cologists p = 0.222, and clinical oncologists versus medical
oncologists p = 0.810). 7.1 % of specialists communicated
an inappropriate interpretation to patients. 6.5 % were
overly reassuring and 0.6 % would have said a BRCA2 mu-
tation contributed to causing the breast cancer.
There was more uncertainty around both the interpret-
ation, and communication and management of genetics re-
port 2 in comparison to report 1. Most free text responses
for reports 1 and 2 were themed around whether a geneti-
cist would/should be interpreting these results rather than
breast cancer specialist as this was a ‘complicated result’.
One specialist discussed the pre-test risk being high in re-
port 1 and therefore considering surveillance and risk re-
ducing options despite no clear pathogenic mutation. For
report 2 one surgeon said he/she would not have referred
this patient without a family history.
Geneticists survey – questionnaire 2
The geneticist’s survey was sent to the members of the
ENIGMA consortium [22] who further distributed the
survey and 175 responses were received from 21
countries. Of the 61 medical geneticists who responded
we included only UK practising doctors leaving 31 eli-
gible respondents (Table 4). Most (51.6 %) geneticists
surveyed were aged 40–49 and had been working in gen-
etics for >10 years and discuss test results directly with
patients on one or more occasion per week. Two
thirds showed a copy of the test report to the patient.
Geneticists reported using multiple methods to clarify
VUS significance (median 5, range 0–11). They
mainly worked with busy NHS diagnostic genetic la-
boratories with a 4–8 week time from blood draw to
report. Pathogenic mutations were reported more
commonly (10–20 %) than VUS (1–10 %) in these
UK laboratories. A specific classification system was
used in 11/31 (35.5 %) of laboratory reports (for in-
ternal use) and 12/31 (38.7 %) of clinical reports (re-
port received by the requesting clinician). The same
respondents reported that multiple systems of classifi-
cation were used by their diagnostic laboratories; the
most common was a word based system (pathogenic,
uncertain, polymorphic) in both laboratory and clin-
ical reports (32 %), next most frequently used was a
4 point system based on a review of in-silicon and lit-
erature evidence (in 13 % laboratory and 3 % clinical
reports) and then the 5 point IARC system based on
the multifactorial likelihood of pathogenicity, (10 %
laboratory and 6 % clinical reports). BRCA test re-
quests were accepted from clinicians in a genetics
clinic or from allied professions with genetics qualifi-
cations. Very few were accepted from clinicians in
oncology clinics or from patients.
Discussion
This survey was designed to gain a snapshot of the
broad understanding of VUS’s amongst non-geneticist
breast cancer specialists in the UK. We tested their in-
terpretation and anticipated patient communication
Table 3 Categorising communication to patient responses by breast cancer specialists
Total Medical oncologist Clinical oncologist Surgeon
No. (%) No. (%) No. (%) No. (%)
155 (100 %) 63 (40.7 %) 54 (34.8 %) 38 (24.5 %)
Report 1
Appropriate 146 (94.2 %) 62 (98.4 %) 50 (92.6 %) 34 (89.5 %)
Inappropriate 2 (1.3 %) 1 (1.6 %)a 1 (1.9 %) 0 (0 %)
Don’t know 7 (4.5 %) 0 (0 %) 3 (5.6 %) 4 (10.5 %)
Report 2
Appropriate 83 (53.5 %) 35 (55.6 %) 28 (51.9 %) 20 (52.6 %)
Inappropriate 11 (7.1 %) 2 (3.2 %) 3 (5.6 %) 6 (15.8 %)
Don’t know 61 (39.4 %)b 26 (41.3 %) 23 (42.6 %) 12 (31.6 %)
a‘Other: Probable pathogenic mutation so advice is on assumption that this is pathogenic ....’
bIncludes: Other (n = 3): “These questions are hard to answer when we don't deal with interpreting these reports day to day” (n = 1); “just read about it before seeing
patient” (n = 1), “why did I send her for genetic testing?? I wouldn't have done so with no FH!!!” (n = 1)
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using two actual reports where a VUS had been identi-
fied. Our study demonstrates that most breast cancer spe-
cialists currently directly refer their patients to genetics
service for a BRCA test. Perceived genetics knowledge is
not uniform over differing specialities although genetics
training is mainly limited to undergraduate level or as part
of preparation for postgraduate exams. Overall the major-
ity of survey respondents felt uncertain about their ability
to understand the implications of the reported variants
based on the genetics reports they were presented with.
There was a significant difference between specialities
with surgeons feeling more confident than medical oncol-
ogists (p = 0.030). The results from report 2 highlight the
potential for wide variation in interpretation of genetics
reports by non-geneticists and the uncertainty around
management generated particularly in a patient without a
family history of breast or ovarian cancer. However this
group of patients with for example young onset triple
negative breast cancer but no family history are those who
are most likely to be tested directly in the oncology clinic
as part of the mainstreaming agenda.
The geneticists that responded to the survey reported
that their laboratories reported fewer VUS as a propor-
tion of all reports (1–10 %) than might be anticipated
from the literature or was thought to be likely by the
breast cancer specialists surveyed (10–20 %). This may
be because with increasing volumes of tested and
reported BRCA tests over many years, a previously clas-
sified VUS may be more often recognised as polymor-
phisms in the tested population and therefore no longer
reported as a VUS.
We deliberately chose two recent genetic test reports
from laboratories where differing presentation styles re-
flect the variation in UK Genetics laboratories report
format. There is no standardised national reporting tem-
plate and not all laboratories give clear clinical guidance
on management (i.e. for a VUS this would be a clear
statement that the VUS should NOT be used for pre-
dictive testing and that the family history should guide
management) [8, 23]. Equally there is no consensus sur-
rounding a single classification method for VUSs within
the genetics community [24, 25] as further demonstrated
by the results of our geneticists survey where multiple
classification systems were used with no clear majority
Table 4 Medical geneticists questionnaire results (n = 31)
Number Percentage
Age category
30–39 5 16.1 %
40–49 16 51.6 %
50–59 8 25.8 %
60+ 2 6.5 %
Length of time working in genetics
< 5 years 1 3.1 %
5–10 years 8 25.8 %
>10 years 22 71.0 %
Patient contact
Do you discuss test results directly
with patients?
Never 2 6.5 %
Rarely (1–2/yr) 0 0 %
Sometimes (1–2/month) 4 12.9 %
Regularly (≥1 per week) 25 80.6 %
Do patients see a copy of the
BRCA testing report?
Yes 8 25.8 %
Sometimes 11 35.5 %
No 3 9.7 %
Not sure/missing 9 29.0 %
Acceptance of BRCA test requestsa Yes No
Clinicians in genetics clinic 26 (83.9 %) 0 (0 %)
Clinicians in oncology clinic 3 (9.7 %) 19 (61.3 %)
Primary care/family doctor 1 (3.2 %) 23 (74.2 %)
Allied professionals with
genetics qualification
23 (74.2 %) 2 (6.5 %)
Patients 1 (3.2 %) 22 (71.0 %)
Lab capacity and reporting Most common
response
No. (%)
No. of patient samples tested per year 100–500 17 (54.8 %)
Proportion reporting clearly
pathogenic mutation
10–20 % 17 (54.8 %)
Proportion reporting a VUS 1–10 % 12 (38.7 %)
Length of test time
(blood draw- report)
4–8 weeks 13 (41.0 %)
Methods to clarify significance
of a VUS
Colleague discussion 23 74.2 %
Information from other
lab/clinical expert
16 51.6 %
Co-segregation (additional
blood from family)
23 74.2 %
Literature search 20 64.5 %
Mutation database search 15 48.4 %
Google search 9 29.0 %
Table 4 Medical geneticists questionnaire results (n = 31)
(Continued)
Splicing prediction software 7 22.6 %
Conservation database 7 22.6 %
Tumour pathology report 7 22.6 %
Tumour DNA 5 16.1 %
Other: RNA studies 2 6.5 %
aNumbers exceed 100 % as multiple responses allowed
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leader. This can lead to further confusion when non-
geneticists receive reports potentially from different la-
boratories. The American College of Medical Genetics
and Genomics and the Association for Molecular
Pathology have issued a joint guideline for interpretation
of sequence variants [26].
Multiple approaches aimed at understanding the
pathogenicity of a variant in any gene exist and these are
set out in the ACGS guidelines [13]. Some methods in-
volve in-silico analysis but some require additional sam-
ples from other affected family members or tumour
samples to fully assess [12, 25, 27]. From this survey it
can be seen that UK geneticists commonly adhere to
guidelines and use multiple methods (median 5). These
independent lines of evidence are more powerful if com-
bined and can be used to give a posterior probability of
pathogenicity of a BRCA VUS with resulting classifica-
tion that can be linked to clinical actions [20, 25]. Thus,
for a VUS, referral onwards to the genetics services is a
necessary action; however, it is important for referring
clinicians to convey to their patients that most VUS are
not pathogenic, most remain of unclear significance and
very few end up with sufficient additional evidence to
formally move into IARC Class 4 (i.e. sufficiently certain
to be used as a predictor of future risk).
Other studies have found varying knowledge of breast
cancer genetics by physicians. A survey looking at US
oncologist’s general BRCA knowledge found only 40 %
correctly answered all 4 questions [19]. In contrast a
Dutch survey reported better knowledge on hereditary
breast cancer by surgeons, medical and radiation oncolo-
gists and radiologists with average score of 6.1/7 cor-
rectly answered questions [17]. However neither study
specifically looked at BRCA VUS knowledge. Certainly
there is considerable scope for physician (and patient)
misunderstanding of BRCA results leading to inappro-
priate patient care [28, 29] and uncertainty about clinical
management [23]. In our study most breast cancer spe-
cialists correctly interpreted report 1 but found report 2
more challenging with a greater degree of uncertainty.
The additional burden of an uncertain genetic test re-
sult during the emotionally charged time of a cancer
diagnosis may encourage patients towards risk reducing
surgery that may be inappropriate. Several studies report
risk reducing surgery rates amongst patients receiving a
VUS result. These vary widely from similar to those
tested and receiving a negative report 7–10 % RRM [14, 30]
to high rates (42 %) within one year after receiving a VUS
result [31]. Genetic testing at the time of cancer diagnosis,
sometimes called “treatment focused genetic testing” is
already part of the mainstreaming agenda for more perso-
nalised treatment and is being implemented routinely in
some areas of the UK particularly with a view to facilitating
entry into clinical trials. The GTEOC study [32] is looking
at upfront genetic testing at time of ovarian cancer diagno-
sis irrespective of family history and the OlympiAD trial
[33] is recruiting BRCA gene carriers with distant metasta-
ses. Trials of targeted therapies in BRCA mutation carriers
in the adjuvant setting are now recruiting and require early
identification of gene carriers.
Patients find that genetic counselling is helpful
(>90 %) and reduces cancer distress [14]. Yet genetic
counselling services in the NHS have insufficient re-
source to manage the inevitable increase on demand for
rapid testing. Mainstreaming is inevitable and this study
demonstrates that there is an urgent need to ensure not
only adequate education in germline genetic testing for
cancer specialists but also integration of the cancer gen-
eticist into the multidisciplinary team. Agreement of a
national reporting template to provide unambiguous test
reports to the receiving non-expert clinician with clear
instructions for the clinical utilisation of the test result
that can be audited is needed.
Limitations
As with all studies using survey methodology, data col-
lection is limited by selection bias of respondents most
interested in the subject matter. It is recognised that the
answers in the interpretation of the reports were not
mutually exclusive and therefore there may have been
more than one “correct” answer depending on the
participant’s interpretation.
Conclusion
We conclude that at present UK non-genetics trained
breast cancer specialists would require additional train-
ing to competently deliver VUS results directly to the
patient and incorporate results into an appropriate man-
agement plan. A multi-disciplinary approach will remain
crucial. The adoption by all genetics laboratories of a
standard reporting template and a single classification
system linked to clear clinical actions would greatly
assist the safe integration of germline genetic testing into
the mainstream of oncology practice.
Additional file
Additional file 1: Interpretation and communication to patient of
BRCA test report. Report 1. You sent your female breast cancer patient
who has a strong family history (mother and aunt) of breast cancer for
genetic testing. She returns to clinic and you have to explain this report
to her. Report 2. You sent your female breast cancer patient who has
NO family history of breast cancer for genetic testing. She returns to
clinic and you have to explain this report to her. (DOC 26 kb)
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